#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glioblastoma multiforme Antiphospholipid antibodies Malignant neoplasm of choroid Follicular lymphoma stage I Solitary fibrous tumour Primary myelofibrosis Neuroendocrine tumour of the lung Cutaneous T-cell lymphoma refractory Neuroendocrine carcinoma Hepato-lenticular degeneration Hypocalcaemia Nephrotic syndrome Frostbite Endometrial cancer Liposarcoma metastatic More trials…

    Learn about Rare Diseases

    Synovial sarcoma recurrent – Treatment Familial haemophagocytic lymphohistiocytosis – Basic Information Adrenogenital syndrome – Life with Disease Richter’s syndrome – Diagnostics Hepatic angiosarcoma – Diagnostics Epidermolysis bullosa – Basic Information Leiomyosarcoma metastatic – Basic Information Mucopolysaccharidosis I – Basic Information Toxic epidermal necrolysis – Life with Disease Osteosarcoma metastatic – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gs-4182 Rosnilimab Erythromycin Lactobionate Botaretigene Sparoparvovec Cipepofol Cenerimod Lenograstim Tozorakimab Trientine Dihydrochloride Methoxsalen Midodrine Hydrochloride Povetacicept Namodenoson Sulfur Hexafluoride Estradiol Hemihydrate Phenylephrine Hydrochloride Lenzumestrocel Dexamethasone Phosphate Fitusiran Gentamicin Sulfate More therapies…

    Learn about Your Condition

    Immune-mediated renal disorder Malignant oligodendroglioma Cutibacterium acnes infection Malignant melanoma of eyelid Skin cancer Nephropathy Infant sedation Penile squamous cell carcinoma Breast angiosarcoma Escherichia infection Papilloma viral infection Phaeochromocytoma Embolism venous Ovarian cancer stage IV Lung adenocarcinoma stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Zazabie s.r.o.

Zazabie s.r.o.

Hlavna 38/70, Stare Mesto, Kosice, 040 01, Slovakia

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

    Recruiting

    3 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Entecavir
    • Ianalumab
    • Tenofovir Disoproxil
    Bulgaria Czechia France Germany Hungary Italy +5

  • Phase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Entecavir
    • Ianalumab
    • Tenofovir Disoproxil
    Bulgaria Czechia Hungary Poland Portugal Slovakia +1

  • Study on the Effects of Upadacitinib in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE)

    Not recruiting

    3 1
    Investigated Drugs:
    • Upadacitinib
    Belgium Bulgaria Croatia Estonia France Germany +10

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!